N-Gene Inc. was founded in 1997 for developing a family of proprietary, small molecules to address a wide range of adverse medical conditions. The lead molecule of the company’s late-stage portfolio – BGP-15 – was initially developed for insulin resistance and reached phase 2 human clinical stage.
Recent pre-clinical studies and findings of complex and diverse mode-of-action suggest that BGP-15 is an ideal candidate for a diverse orphan portfolio.
To exploit these new findings N-Gene has signed a licensing agreement with Mitochon Technologies and Vudbenk Life Science, which companies are continuing BGP-15’s orphan development.
Our Advisory Team
Michael Brownstein, Ph.D., M.D., our Senior Advisor earned his bachelor’s degree at Columbia University and an M.D. and Ph.D. at the University of Chicago. He received his clinical training at the Boston Children’s Hospital and then moved to the National Institutes of Health to work with Julius Axelrod, recipient of a Nobel Prize in 1970 for his studies in the field of neuropharmacology. Dr. Brownstein remained at NIH after completing his fellowship, and served as Chief of the Laboratory of Genetics of the National Institute of Mental Health and the National Human Genome Research Institute. For two years, he was the Scientific Director of the NIMH Intramural Research Program. While at the NIMH/NHGRI, he directed the Brain Molecular Anatomy Project. Simultaneously, he contributed to the Mammalian Gene Collection, a trans-Institutional effort to clone and sequence cDNAs corresponding to all human, mouse, and rat transcripts. Subsequently he directed the functional genomics program at the J. Craig Venter Institute in Rockville, MD for three years. He has worked in the fields of neurobiology, neuroendocrinology, biochemical pharmacology, genetics, and genomics; has published more than 300 papers in peer reviewed journals; and has served on major editorial boards and continues to serve on a number of scientific advisory boards. He is the co-founder of several successful bio-pharmaceutical companies.
Zsolt Harsanyi, Ph.D. received a Ph.D. from Albert Einstein College of Medicine and a B.A. from Amherst College. Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress’ Office of Technology Assessment, served as a consultant to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell University Medical College. He was a founder of Dynport Vaccine Company LLC and vice president of corporate finance at E.F. Hutton, Inc. Dr. Harsanyi served as president of Porton International plc, a pharmaceutical and vaccine company, chief executive officer and chairman of the board of directors of Exponential Biotherapies Inc., a private biotechnology company, and director of Aptevo Therapeutics.
Professor Mark Febbraio is a Senior Principal Research Fellow of the Australian Government’s National Health and Medical Research Council, and the Head of the Cellular and Molecular Metabolism Laboratory within the Drug Discovery Program at Monash Institute of Pharmaceutical Sciences, Monash University Australia. He is also the Founder and CSO of the recently incorporated company Kinomedica. His research is focussed on understanding mechanisms associated with exercise, obesity, type 2 diabetes and cancer and his aim is to develop novel drugs to treat lifestyle related diseases. He has authored over 260 peer reviewed papers in leading journals, has over 35,000 career citations and an H factor of 105. He has won prizes at international, national and institutional levels including the A K McIntyre Prize for significant contributions to Australian Physiological Science (1999), the ESA/ADS Joint Plenary Lecture (2009), the Sandford Skinner Oration from the University of Melbourne (2011), Eureka Scientific Prize Finalist (2013) and the Kellion Award for the Australian Diabetes Society (2017).
Kalman Tory, M.D., Ph.D., our medical advisor received his M.D. and Ph.D. degrees at Semmelweis University, Budapest. After a short clinical training he joined the Institute of Drug Research, Budapest and took part in the development of three new antitumor drug candidates. He had a fellowship at the Laboratory of Immunobiology at NCI, Frederick, MD, US, then at the same institute he took part in the Human Genome project as a group leader for three more years. He worked on the building of a genetic map of human chromosome 3, furthermore on the cloning and analysis of the von Hippel-Lindau (VHL) tumor suppressor gene. He continued his work on VHL and renal cancer biology at DKFZ, Heidelberg and RWTH, Aachen, Germany. After returning to Hungary, he joined Biorex Ltd and took part in the pharmacological development of new antidiabetic agents. Later he served as a senior adviser at Sanofi for one year. He moved to N-Gene RD Ltd. where he took part in the development of hydroxylamine type drug candidates in various therapeutic directions. He has published more than 60 papers in peer-reviewed journals, and he is the inventor of several pharmacological patents.